| 摘要 |
The present invention provides the use of an anti-CD44 antibody, a (Fab')2, Fab, Fab' fragment thereof, an IgG or IgM isotype thereof, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy.
|
